148 related articles for article (PubMed ID: 29196562)
1. The Role of Bromodomain and Extraterminal Motif (BET) Proteins in Chromatin Structure.
Hsu SC; Blobel GA
Cold Spring Harb Symp Quant Biol; 2017; 82():37-43. PubMed ID: 29196562
[TBL] [Abstract][Full Text] [Related]
2. Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system.
Werner MT; Wang H; Hamagami N; Hsu SC; Yano JA; Stonestrom AJ; Behera V; Zong Y; Mackay JP; Blobel GA
J Biol Chem; 2020 Feb; 295(7):1898-1914. PubMed ID: 31792058
[TBL] [Abstract][Full Text] [Related]
3. The BET Protein BRD2 Cooperates with CTCF to Enforce Transcriptional and Architectural Boundaries.
Hsu SC; Gilgenast TG; Bartman CR; Edwards CR; Stonestrom AJ; Huang P; Emerson DJ; Evans P; Werner MT; Keller CA; Giardine B; Hardison RC; Raj A; Phillips-Cremins JE; Blobel GA
Mol Cell; 2017 Apr; 66(1):102-116.e7. PubMed ID: 28388437
[TBL] [Abstract][Full Text] [Related]
4. The conserved 12-amino acid stretch in the inter-bromodomain region of BET family proteins functions as a nuclear localization signal.
Fukazawa H; Masumi A
Biol Pharm Bull; 2012; 35(11):2064-8. PubMed ID: 22971749
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Bromodomain and Extraterminal Domain is Associated with Progression, Metastasis and Unfavorable Outcomes: Highlighting Prognostic and Therapeutic Value of the BET Protein Family in Gastric Cancer.
Fard SS; Kouchaki S; Salimian Z; Sotoudeh M; Mousavi SA; Alimoghaddam K; Ghaffari SH
Anticancer Agents Med Chem; 2023; 23(7):794-806. PubMed ID: 36284375
[TBL] [Abstract][Full Text] [Related]
6. Functions of BET proteins in erythroid gene expression.
Stonestrom AJ; Hsu SC; Jahn KS; Huang P; Keller CA; Giardine BM; Kadauke S; Campbell AE; Evans P; Hardison RC; Blobel GA
Blood; 2015 Apr; 125(18):2825-34. PubMed ID: 25696920
[TBL] [Abstract][Full Text] [Related]
7. The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators.
Wai DCC; Szyszka TN; Campbell AE; Kwong C; Wilkinson-White LE; Silva APG; Low JKK; Kwan AH; Gamsjaeger R; Chalmers JD; Patrick WM; Lu B; Vakoc CR; Blobel GA; Mackay JP
J Biol Chem; 2018 May; 293(19):7160-7175. PubMed ID: 29567837
[TBL] [Abstract][Full Text] [Related]
8. Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers.
Nguyen MV; Loof L; Falchook GS
J Immunother Precis Oncol; 2020 Feb; 3(1):16-22. PubMed ID: 35756176
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis provides a BRD's eye view of BET protein function.
Stonestrom AJ; Hsu SC; Werner MT; Blobel GA
Drug Discov Today Technol; 2016 Mar; 19():23-28. PubMed ID: 27769353
[TBL] [Abstract][Full Text] [Related]
10. Emerging roles of BET proteins in transcription and co-transcriptional RNA processing.
Eischer N; Arnold M; Mayer A
Wiley Interdiscip Rev RNA; 2023 Jan; 14(1):e1734. PubMed ID: 35491403
[TBL] [Abstract][Full Text] [Related]
11. The Functions of BET Proteins in Gene Transcription of Biology and Diseases.
Cheung KL; Kim C; Zhou MM
Front Mol Biosci; 2021; 8():728777. PubMed ID: 34540900
[TBL] [Abstract][Full Text] [Related]
12. BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell.
Deeney JT; Belkina AC; Shirihai OS; Corkey BE; Denis GV
PLoS One; 2016; 11(3):e0151329. PubMed ID: 27008626
[TBL] [Abstract][Full Text] [Related]
13. Bromodomain and Extraterminal Domain Protein 2 in Multiple Human Diseases.
Ji Y; Chen W; Wang X
J Pharmacol Exp Ther; 2024 May; 389(3):277-288. PubMed ID: 38565308
[TBL] [Abstract][Full Text] [Related]
14. Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction.
Crowe BL; Larue RC; Yuan C; Hess S; Kvaratskhelia M; Foster MP
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2086-91. PubMed ID: 26858406
[TBL] [Abstract][Full Text] [Related]
15. BET bromodomain inhibitors: a patent review.
Garnier JM; Sharp PP; Burns CJ
Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers.
Sun HY; Du ST; Li YY; Deng GT; Zeng FR
World J Gastrointest Oncol; 2022 Jan; 14(1):75-89. PubMed ID: 35116104
[TBL] [Abstract][Full Text] [Related]
17. Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases.
Morgado-Pascual JL; Rayego-Mateos S; Tejedor L; Suarez-Alvarez B; Ruiz-Ortega M
Front Pharmacol; 2019; 10():1315. PubMed ID: 31780938
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
19. Functional coordination of BET family proteins underlies altered transcription associated with memory impairment in fragile X syndrome.
Kim SK; Liu X; Park J; Um D; Kilaru G; Chiang CM; Kang M; Huber KM; Kang K; Kim TK
Sci Adv; 2021 May; 7(21):. PubMed ID: 34138732
[TBL] [Abstract][Full Text] [Related]
20. [Susceptibility study on the germline rare variants of bromodomain and extraterminal domain protein family-encoding genes and patients with cancer living in some regions of China].
Huang Y; Li JH; Wang X; Zou Y; Huang WF; Liu C; Zhang H
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(42):3374-3381. PubMed ID: 36372767
[No Abstract] [Full Text] [Related]
[Next] [New Search]
